A proof-of-concept study on a universal standard kit to evaluate the risks of inspectors for their foundational ability of visual inspection of injectable drug products.

Q3 Medicine
Hirohito Katayama, Manabu Tsuda, Yukari Koga, Nobuaki Habasaki, Kosuke Taniyama, Yuichi Minato, Akihiro Oda, Kouichi Nagata, Takashi Amagasa, Kimitaka Misawa
{"title":"A proof-of-concept study on a universal standard kit to evaluate the risks of inspectors for their foundational ability of visual inspection of injectable drug products.","authors":"Hirohito Katayama, Manabu Tsuda, Yukari Koga, Nobuaki Habasaki, Kosuke Taniyama, Yuichi Minato, Akihiro Oda, Kouichi Nagata, Takashi Amagasa, Kimitaka Misawa","doi":"10.5731/pdajpst.2023.012911","DOIUrl":null,"url":null,"abstract":"<p><p>Visual inspectors' ability to detect foreign matter in injections must be qualified for each product type or bracketing group, as stated in the United States Pharmacopeia <1790>. The common defect criterion is ″visible″ However, this qualitative lower rejection limit is based on the premise that the nature of human inspection at one site is globally comparable to that at all other sites. If not, the ″visible″ foreign matter can vary among inspector groups for each product, leading to quality differences between sites. Inspectors are trained and qualified using ″visible″ foreign matter samples from their site; therefore, inspectors' ability to detect foreign matter can differ due to different standards. Japanese pharmaceutical companies import injections and perform secondary visual inspections because variations in ″visible″ ability arise due to individual differences among regions. Currently, there is no universal method for comparing ″visible″ rejection zones among manufacturing sites for different products because product-specific standard samples for qualifications cannot be universalized. Therefore, instead of comparing the product-specific ″visible″ standard sample, this study proposes a novel universal particle standard challenge kit to compare sites' or inspectors' inner ″visible″ detection ability. Our results suggest that the proposed kit could evaluate the comparability of ″visible″ at each site and for each inspector but not on sites' ″visible″ standard samples. The primary challenge in implementing a universal standard lies in the inherent bias of inspectors already acclimated to specific products. This study found that an inspectors' foundational ability can be evaluated by canceling the bias via rapid and effective training in cases of simple standard samples. Our results suggest that using a universal standard kit to assess an inspector's fundamental ability to detect ″visible″ foreign matter is feasible. The study does not aim to replace the inspectors' product qualifications but to compare their inner ability for risk assessment.</p>","PeriodicalId":19986,"journal":{"name":"PDA Journal of Pharmaceutical Science and Technology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PDA Journal of Pharmaceutical Science and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5731/pdajpst.2023.012911","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Visual inspectors' ability to detect foreign matter in injections must be qualified for each product type or bracketing group, as stated in the United States Pharmacopeia <1790>. The common defect criterion is ″visible″ However, this qualitative lower rejection limit is based on the premise that the nature of human inspection at one site is globally comparable to that at all other sites. If not, the ″visible″ foreign matter can vary among inspector groups for each product, leading to quality differences between sites. Inspectors are trained and qualified using ″visible″ foreign matter samples from their site; therefore, inspectors' ability to detect foreign matter can differ due to different standards. Japanese pharmaceutical companies import injections and perform secondary visual inspections because variations in ″visible″ ability arise due to individual differences among regions. Currently, there is no universal method for comparing ″visible″ rejection zones among manufacturing sites for different products because product-specific standard samples for qualifications cannot be universalized. Therefore, instead of comparing the product-specific ″visible″ standard sample, this study proposes a novel universal particle standard challenge kit to compare sites' or inspectors' inner ″visible″ detection ability. Our results suggest that the proposed kit could evaluate the comparability of ″visible″ at each site and for each inspector but not on sites' ″visible″ standard samples. The primary challenge in implementing a universal standard lies in the inherent bias of inspectors already acclimated to specific products. This study found that an inspectors' foundational ability can be evaluated by canceling the bias via rapid and effective training in cases of simple standard samples. Our results suggest that using a universal standard kit to assess an inspector's fundamental ability to detect ″visible″ foreign matter is feasible. The study does not aim to replace the inspectors' product qualifications but to compare their inner ability for risk assessment.

一项关于通用标准试剂盒的概念验证研究,以评估检查员对注射药物产品进行目视检查的基本能力的风险。
如美国药典所述,视觉检查员检测注射剂中异物的能力必须符合每个产品类型或分类组的要求。常见的缺陷标准是″可见的″然而,这个定性的较低的不合格限制是基于这样一个前提,即在一个地点的人工检查的性质与在所有其他地点的人工检查的性质具有全局可比性。如果没有,″可见的″异物可能会因每个产品的检查员小组而异,从而导致站点之间的质量差异。检查人员经过培训并使用″可见″现场异物样本获得资格;因此,由于不同的标准,检查员检测异物的能力可能会有所不同。日本制药公司进口注射剂,并进行第二次目视检查,是因为各地区的个体差异导致″可见″能力的差异。目前,没有通用的方法来比较不同产品的生产场所之间的″可见″拒收区,因为产品特定的合格标准样品无法通用。因此,本研究提出了一种新的通用颗粒标准挑战试剂盒,以比较站点或检查员的内部″可见″检测能力,而不是比较产品特定的″可见″标准样品。我们的结果表明,所提出的试剂盒可以评估每个站点和每个检查员的″visible″的可比性,但不能评估站点的″visible″标准样品。实施通用标准的主要挑战在于已经适应特定产品的检查员固有的偏见。本研究发现,在简单标准样本的情况下,通过快速有效的培训,可以通过消除偏差来评估检查员的基础能力。我们的研究结果表明,使用通用标准试剂盒来评估检查员检测″可见″异物的基本能力是可行的。这项研究的目的不是取代检查员的产品资格,而是比较他们内在的风险评估能力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.90
自引率
0.00%
发文量
34
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信